Article Text

Download PDFPDF

Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis
Free
  1. R Alten1,
  2. E Gromnica-Ihle2,
  3. C Pohl1,
  4. J Emmerich2,
  5. J Steffgen3,
  6. R Roscher3,
  7. R Sigmund3,
  8. B Schmolke4,
  9. G Steinmann3
  1. 1Rheumatologie und Physikalische Therapie, Schlossparkklinik, Heubnerweg 2, D-14059 Berlin, FRG
  2. 2Rheumaklinik Buch, Karowerstr 11, D-13125, Berlin-Buch, FRG
  3. 3Boehringer Ingelheim Pharma KG, Birkendorfer Strasse 65, D-88397 Biberach an der Riss, FRG
  4. 4Labor für Klinische Immunologie, Potsdamer Chaussee 80, D-14129 Berlin-Zehlendorf, FRG
  1. Correspondence to:
    Professor G Steinmann
    Birkendorfer Strasse 65, 88397 Biberach/Riss, Germany; Gerhard.Steinmannbc.boehringer-ingelheim.com

Abstract

Background: Leukotriene B4 (LTB4) has a key role in the pathophysiology of rheumatoid arthritis (RA).

Objective: To investigate the inhibition of ex vivo LTB4-induced Mac-1 (CD11b/CD18) expression in leucocytes of patients with RA by the new oral LTB4 receptor antagonist BIIL 284.

Methods: The pharmacokinetics and inhibition of LTB4-induced Mac-1 expression of BIIL 284 were characterised in 26 adult patients with RA who were treated with BIIL 284 25 mg, 150 mg, or placebo given once a day for 14 days according to a double blind, randomised, parallel group design.

Results: Tmax of BIIL 315 in plasma (main metabolite and active principle of BIIL 284 in plasma) was achieved about four hours after drug administration, and Cmax,ss and AUC0–6h,ss increased in proportion to the dosage. 100% inhibition of LTB4-induced MAC-1 expression was reached after two hours (150 mg) or four hours (25 mg), showing a statistically significant difference in comparison with placebo (p<0.005). A longlasting dynamic effect was seen consistently even when plasma concentrations declined to very low values 24 hours after administration. Secondary clinical efficacy end points remained unchanged probably owing to the short duration of treatment. Adverse events (AEs) were reported in 12 patients during the study. No serious AEs or laboratory AEs were seen.

Conclusions: Both the 25 mg and 150 mg doses of BIIL 284 safely and effectively inhibit Mac-1 expression on neutrophils; thus longer treatment with BIIL 284 may result in clinical benefit for patients with RA.

  • Mac-1 expression
  • leukotriene B4
  • rheumatoid arthritis
  • clinical trial
  • pharmacokinetics
  • ACR, American College of Rheumatology
  • AE, adverse event
  • CRP, C reactive protein
  • DAS, Disease Activity Score
  • DMARD, disease modifying antirheumatic drug
  • ESR, erythrocyte sedimentation rate
  • HPLC, high performance liquid chromatography
  • IME, induced Mac-1 expression
  • LTB4, leukotriene B4
  • MS, mass spectrometry
  • SJC, swollen joint count
  • TJC, tender joint count
  • TNF, tumour necrosis factor

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.